NASDAQ$UTHR
United Therapeutics Corp · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Reported highest quarterly revenue in history, driven by Tyvaso growth and Tyvaso DPI launch.
United Therapeutics Corporation reported a 16% year-over-year increase in total revenues for the third quarter of 2022, reaching $516.0 million compared to $444.7 million in the third quarter of 2021. Net income also increased by 47% to $239.3 million, compared to $162.7 million in the same period of the previous year.
- Total revenues grew 16% year-over-year to $516.0 million.
- Net income increased 47% year-over-year to $239.3 million.
- Tyvaso became the first $1 billion annual run rate product.
- Tyvaso DPI launch contributed to the company's growth trajectory.
Headline financials
Revenue & EPS history
United Therapeutics · Revenue · Quarterly
$516M
Revenue by segment
United Therapeutics · $516M total across 5 segments · Q3 2022
- Nebulized Tyvaso$258M+56.9%49.9%
- Remodulin$114M-9.1%22.1%
- Orenitram$87.5M+2.7%17.0%
- Unituxin$46.1M-16.6%8.9%
- Adcirca$10.7M-26.7%2.1%
Forward guidance
The company is focused on revenue growth, achieving 6,000 patients on Tyvaso by the end of 2022, and continuing clinical trials and research and development plans.
Tailwinds
- Revenue growth prospects
- Goal of achieving 6,000 patients on Tyvaso by the end of 2022
- Clinical trials and other research and development plans, including the TETON studies of Tyvaso
- ADVANCE studies of ralinepag
- Clinical study of the CLES technology for EVLP
Headwinds
- Risks and uncertainties described in periodic reports filed with the Securities and Exchange Commission
- Factors that could cause actual results to differ materially from anticipated results
- Cautionary statements and risk factors set forth in periodic reports and documents filed with the Securities and Exchange Commission
- Most recent Annual Report on Form 10-K
- Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2022
+0.6%
Avg return
Earnings day
+0.2%
Avg return
5 days after
+1.1%
Avg return
30 days after
57%
39 / 68 earnings
Positive
+16.2%
Q3 2022
Best reaction
-13.0%
Q4 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.3% | -0.4% | -4.0% | |
| Q4 2025 | +13.1% | +8.5% | +10.4% | |
| Q3 2025 | +9.7% | +5.6% | +17.0% | |
| Q1 2025 | +0.8% | -0.7% | +6.0% | |
| Q4 2024 | -10.8% | -13.3% | -14.1% | |
| Q3 2024 | +6.0% | +6.8% | +5.0% | |
| Q2 2024 | -2.9% | -3.5% | +7.7% | |
| Q1 2024 | +10.2% | +11.2% | +17.4% | |
| Q4 2023 | +1.6% | +4.4% | +11.1% | |
| Q3 2023 | +2.4% | +2.4% | +8.0% | |
| Q2 2023 | -3.4% | -1.0% | -5.0% | |
| Q1 2023 | -5.7% | -8.0% | -5.1% | |
| Q4 2022 | -2.7% | -3.3% | -13.8% | |
| Q3 2022 | +16.2% | +16.8% | +22.0% | |
| Q2 2022 | -1.5% | -2.7% | -0.8% | |
| Q1 2022 | +4.1% | -0.6% | +27.2% | |
| Q4 2021 | -13.0% | -14.0% | -9.5% | |
| Q3 2021 | +4.8% | +5.1% | -3.2% | |
| Q2 2021 | +13.7% | +15.0% | +16.7% | |
| Q1 2021 | -1.7% | -2.8% | -9.9% | |
| Q4 2020 | -2.1% | -0.6% | -0.7% | |
| Q3 2020 | +5.6% | +8.6% | +9.8% | |
| Q2 2020 | +0.3% | +2.9% | -6.3% | |
| Q1 2020 | -0.2% | +2.0% | +7.5% | |
| Q4 2019 | -10.7% | -8.0% | -19.1% | |
| Q3 2019 | +3.3% | +3.6% | +6.1% | |
| Q2 2019 | +4.5% | -0.5% | +3.8% | |
| Q1 2019 | -1.3% | -1.9% | -18.1% | |
| Q4 2018 | +3.6% | -1.5% | -3.8% | |
| Q3 2018 | -6.2% | -6.2% | -3.7% | |
| Q2 2018 | +0.3% | +0.7% | +0.1% | |
| Q1 2018 | -8.3% | -8.3% | -4.2% | |
| Q4 2017 | -12.9% | -14.1% | -20.4% | |
| Q3 2017 | +0.2% | +0.8% | +5.1% | |
| Q2 2017 | -2.3% | -2.6% | -2.2% | |
| Q1 2017 | -1.0% | +1.0% | -2.2% | |
| Q4 2016 | -12.2% | -9.2% | -16.6% | |
| Q3 2016 | +4.5% | +6.0% | +19.0% | |
| Q2 2016 | +6.9% | +11.2% | +7.6% | |
| Q1 2016 | -10.6% | — | — | |
| Q4 2015 | -4.2% | — | — | |
| Q3 2015 | +8.8% | — | — | |
| Q2 2015 | +0.8% | — | — | |
| Q1 2015 | -4.4% | — | — | |
| Q4 2014 | +2.3% | — | — | |
| Q3 2014 | -1.9% | — | — | |
| Q2 2014 | +2.7% | — | — | |
| Q1 2014 | +12.4% | — | — | |
| Q4 2013 | -4.1% | — | — | |
| Q3 2013 | +3.8% | — | — | |
| Q2 2013 | +2.7% | — | — | |
| Q1 2013 | -1.6% | — | — | |
| Q4 2012 | +2.7% | — | — | |
| Q3 2012 | +2.9% | — | — | |
| Q2 2012 | +8.3% | — | — | |
| Q1 2012 | +0.8% | — | — | |
| Q4 2011 | -0.9% | — | — | |
| Q3 2011 | +8.0% | — | — | |
| Q2 2011 | +5.0% | — | — | |
| Q1 2010 | -5.3% | — | — | |
| Q1 2011 | +0.8% | — | — | |
| Q4 2008 | +1.8% | — | — | |
| Q4 2010 | +1.8% | — | — | |
| Q3 2009 | +8.0% | — | — | |
| Q3 2010 | +8.0% | — | — | |
| Q4 2009 | -8.2% | — | — | |
| Q2 2010 | -8.2% | — | — | |
| Q2 2009 | -8.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro